BMJ Peter Doshi: Crashes FDA's COVID-19 Vaccine Meeting To Share Data Concerns

The BMJ senior editor Peter Doshi, Ph.D., spoke at the FDA's Vaccines and Related Biological Products Advisory Committee on Wednesday (April 6) and shared the story of whistleblower Brook Jackson. Investigative journalist Paul D. Thacker first reported on Jackson’s accusations against Ventavia Research Group—the Texas-based company Pfizer hired to conduct their pivotal Phase III trial—in an article published in The BMJ, one of the world’s oldest and most prestigious medical journals. Jackson told The BMJ that “the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal Phase III trial.” “The FDA never inspected Ventavia. In fact, the FDA only inspected 9 of the trial’s 150+ sites before approving the vaccine," Peter Doshi told federal vaccine advisors on Wednesday.


bmj.n2635.full
.pdf
Download PDF • 585KB


Sources:


https://www.bmj.com/content/375/bmj.n2635


https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-april-6-2022-meeting-announcement